#GSK – agreement to acquire Nuvalent, Inc. for net estimated $9.4bn

#GSK – 2025 “core EPS” up to 172p, DPS to 66p, growth outlook reaffirmed

#GSK – Q3 results, upgrades FY turnover and earnings guidance

#GSK – Chief Commercial Officer Luke Miels appointed CEO Designate to become CEO at start of next year

#GSK – updates on US settlement of CureVac/BioNTech mRNA patent litigation

#GSK – 2024 “core” EPS up to 159.3p, DPS 61p, provides 2025 growth guidance

#GSK – on Zantac litigation, “Florida State Court's ruling finds in favour of GSK and other defendants”

#GSK – agrees to sell remaining shares in Haleon (#HLN) at 324p, raising approx. £1.248bn

#GSK – 2023 adj. EPS up to 155.1p, DPS 58p, notes 2024 growth expectations

The Current Low Share Price Doesn't Seem Fair for this Great British Pharma

Hi Share Hitters. I recently ploughed back into GSK plc (GSK) shares after a giving them a longish holiday. I’d needed the money for a house purchase and had yet to reinvest. But the shares haven’t moved much of late and I rather think there might be more punters out there who’re willing to give the company another chance. Especially as the world seems to be getting less healthy by the minute.

Putting Your Hard-Earned Where it Could Do Most Good and How it Might Fill your Wallet, too

Hello Share Shiners. You probably know I think all of us ought to have some shares in the pharmaceutical game. It’s safe to say that most of your money will go to making a better world. By reducing the chances of early death and easing pain. What better purpose could your dough have?

No surprise that GSK has sold more Haleon shares, GSK is a buy Haleon is not

I was a little busy yesterday, so I missed much of the “excitement” about Metro Bank (MTRO). I have regarded it as a strong avoid for years, as I most recently discussed in May. You can guess who will get the better deal from its desperate selling of various mortgage exposures to other bank names…I will happily continue to avoid the company at all levels. Spot the reality of a higher interest rate world kicking in for more and more corporate names globally!

#GSK – to sell shares in Haleon (#HLN) at 328p, raising a gross approximate £885.6m

Two Medical Giants for Your Consideration as So Many of Us Approach the Final Curtain.

Hello Share Pals. As this old punter approaches the departure lounge of life, I’m reminded of two important trends for share shifters like us. There are many more people of my vintage and beyond than there used to be. While we are mostly all less healthy than before. In fact, the average age for death is coming down. That can only mean one thing for one important share sector.

#GSK – a Zantac litigation “confidential settlement”, argues “will continue to vigorously defend itself based on the facts and the science in all other Zantac cases”

The legendary investor Sir John Templeton, Dame Emma Walmsley of GSK fame…and me

Decades and decades ago when I started to get into the world of investments, I remember learning the wise words of Sir John Templeton that “the four most dangerous words in investing are: this time it’s different”. Of course, he is absolutely correct, which brings us nicely onto a couple of changes I am considering to my pension fund.

BATS and GSK react to disappointments differently…

I hope to have visited nicely over one hundred different countries before I go to a better place, but I reckon my chances of visiting North Korea are a bit light. I have been thinking about the country a few times over the last week for various reasons, but even I was surprised yesterday to read on British American Tobacco (BATS) an “agreement reached with DOJ and OFAC to resolve investigations into BAT's historical business activities in relation to North Korea from 2007-2017”.

Spring forward (and don’t worry too much about the markets)

I decided to go to bed early last night, to lose an hour on Saturday evening rather than Sunday morning. It is a bit like money really, as given a choice I would much rather spend any cash I have earned in my account, than take out a loan. However, I guess the average bank does alright out of its average credit card issued to its average customer…until at least one of them doesn’t. 

Why FTSE 100 stocks such as GSK and Vodafone are always worth thinking about (but only one of them is a buy today)

Many, many years ago, I remember somebody saying to me that investing in FTSE 100 stocks was pointless as “everything is priced in very efficiently”. What utter rubbish (as I told them at the time). Whilst the world of large cap stocks is covered by more analysts and mentioned more frequently by the press and financial TV, there are still plenty of opportunities to materially beat the index. And that is why today’s updates from both Vodafone (VOD) and (the previously named GlaxoSmithKline) GSK plc (GSK) are worth (at least) thinking about.

#GSK – 2022 adj. EPS up to 139.7p, 2023 outlook includes still expected dividend per share of 56.5p